Comment
GROW® exclusively distributes products in the UK for top US, Canadian and Australian manufacturers, including Nasdaq-listed brands such as Tilray, the $2bn market cap cannabis pharmaceuticals business. GROW® also offers its own in-house product, which is the UK’s best-selling medical cannabis product, and this is protected by a suite of patents.
-
Distributes to 80 clinicians, with 3,000 patients receiving monthly prescriptions
-
Over 50% market share by revenue
-
Increased turnover 5x last year to £5.2m and on track to near double digit revenue in 2022
-
Targeting turnover of more than £300m by 2026
The GROW® team is raising capital in order to ramp up their UK operations and they will also use the funding to scale up activities in the German market and at their facility in Spain.
If you would like to find out more about their plans and download full details about this exciting investment opportunity, please register directly on the Growthdeck website. It’s free, only takes a few minutes of your time, and you will gain access to direct tax-efficient investment opportunities in some of the most exciting UK growth companies such as GROW®.
Alternatively, please fill out the contact form below and a member of the Growthdeck team will be in touch to answer any queries you might have and introduce you to our award-winning service.
